Adaptimmune Therapeutics PLC — Director's Dealing 2023

Jul 3, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2023-07-03

Reporting Person: Sigal Charles Elliott (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-07-03	Option to purchase Ordinary Shares	$0.16	A	933317	Acquired	2033-07-03	Ordinary Shares (933317)	Direct

Footnotes

F1: The exercise price was converted from GBP0.12 based on an exchange rate of $U.S. 1.270841 to GBP1.00. The actual exercise price will be the pounds sterling amount.